Effectiveness of lymphoplasmapheresis compared with therapeutic plasma exchange for thrombotic thrombocytopenic purpura: a retrospective evaluation

Figures & data

Table 1. Baseline characteristics of the 45 patients with TTP.

Characteristics	Normal range	All patients, n=45	LPE,n=27	TPE, n=18	P
Sex, male/female, n (%)	/	13(28.9)/32(71.1)	8(29.6)/19(70.4)	5(27.8)/13(72.2)	0.89
Etiology, primary/secondary, n (%)	/	28 (62.2) /17 (37.8)	17(63.0)/10(37.0)	11(61.1)/7(38.9)	0.90
Hb, g/L, median (range)	115–150	63.0 (42-104)	63.0 (42-104)	62.5 (44-78)	0.003^a
Schistocyte (%), median (range)	/	3.2 (0.5-40)	3.0(0.5-40)	4.5 (1.2-14.0)	0.67
PLT, 10^9/L, median (range)	125–350	12.0 (3.0-48.0)	12.0 (3.0-48.0)	12.0 (4.0-46.0)	0.32
LDH, U/L, median (range)	120–250	858.0 (160.2-7937)	858.0 (264.0-7937)	848.0 (160.2-2897.0)	0.29
TB, µmol/L, median (range)	1.7-17.1	39.6 (8.1-96.8)	42.2 (8.1-96.8)	38.9 (14.2-89.4)	0.27
DB, µmol/L, median (range)	0-6.8	14.5 (2.6-68.9)	14.8 (2.6-68.9)	14.45 (5.0-23.0)	0.09
PLASMIC, point (range)	/	3.0 (1-5)	3.0 (1-5)	3.0 (2-5)	0.809
Fever, n (%)	/	25 (55.5)	14 (51.9)	11 (61.1)	0.70
Renal impairment, n (%)	/	20 (44.4)	13 (48.1)	7 (38.9)	0.26
Neurological manifestations, n (%)	/	37 (82.2)	22 (81.5)	15 (83.3)	0.32
Hemolysis, n (%)	/	39 (86.7)	23 (85.2)	16 (88.9)	0.34

Hb, hemoglobin concentration; PLT, platelet count; LDH, lactate dehydrogenase; TB, total bilirubin concentrations; DB, direct bilirubin concentrations; TPE, therapeutic plasma exchange; LPE, lymphoplasmapheresis

^a P < 0.05

Table 2. Comparison of clinical values before and after treatment.

Laboratory test	All patients, n=45			TPE, n=18			LPE, n=27
	Pre-treatment	Post-treatment	P	Pre-treatment	Post-treatment	P	Pre-treatment	Post-treatment	P
Hb, g/L, Mean ± SD	64.33 ± 14.74	81.11 ± 20.12	<0.001	65.85 ± 17.43	78.22 ± 19.25	<0.001	62.06 ± 9.39	85.44 ± 21.16	0.006
PLT,109/L, Mean ± SD	15.07 ± 10.98	132.36 ± 106.33	<0.001	14.52 ± 10.13	126.59 ± 117.43	<0.001	15.89 ± 12.41	141.0 ± 89.69	<0.001
LDH, U/L, median (range)	858 (160.2-7937)	264.6 (155-4477.9)	<0.001	848 (160.2-2897)	246 (182-569)	0.003	858 (264-7937)	494.2 (155-4477.9)	0.007
TB, µmol/L, Mean ± SD	41.23 ± 20.83	19.46 ± 24.86	<0.001	40.67 ± 22.31	23.82 ± 30.11	<0.001	39.36 ± 17.84	11.69 ± 5.64	0.003
DB, µmol/L, median (range)	14.5 (2.6-68.9)	4.35 (1.1-51.5)	<0.001	14.45 (5-23)	3.2(2.1-9.3)	<0.001	14.8 (2.6-68.9)	6.5 (1.1-51.5)	0.018

Hb, hemoglobin concentration; PLT, platelet count; LDH, lactate dehydrogenase; TB, total bilirubin concentrations; DB, direct bilirubin concentrations; TPE, therapeutic plasma exchange; LPE, lymphoplasmapheresis

Table 3. In-hospital follow-up.

Outcome	LPE(n=27)	TPE(n=18)	P
Remission, n (%)	16 (59.2)	14 (77.8)	0.20
relapses, n (%)	5 (18.5)	6 (33.3)	0.26
urticaria, n (%)	5 (18.5)	5 (27.8)	0.46
hypocalcemia, n (%)	2 (7.4)	1 (5.6)	0.80
Session number, median (range)	2 (1-10)	4.5 (1-13)	0.04
Plasma volume, median (range)	3100 (1380-14,050)	7300 (1200-29,700)	0.01
Days of inpatient, median (range)	12 (3-50)	15.5 (5-38)	0.30
Cost of inpatient, median (range)	22829 (4197-57,185)	24965 (3305-137,685)	0.08
Median time to remission from admission, day median (range)	9 (2-50)	8 (5-31)	0.75
Median time to remission from first therapy, day median (range)	5 (1-48)	5 (2-22)	0.53

Data availability statement

Data sharing does not apply to this article as no new data were created or analyzed in this study.